GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Can someone point out over on the ADVFN Board that although Merck have a deal with Artios for DNA DDR, Merck also have also a deal with Physiomics for the same thing. Thou the money paid by Merck to the PYC deal is microscopic in comparison with Artios.
Typo-Buy out
I disagree with Kidlington on the possibility of a buy put.Some medium or large Pharma would probably only have to stump up approx £12 mill to take this in house -small change.And someone like Bicycle rather than one of the really large boys may see precision dosing and the expertise they would be purchasing as a field they could gain a foothold in and traction in internationally as it is applied across the medical landscape in multiple uses other than cancer treatments.Taking it on now would mean purchasing and advancing the tech very early doors for basically peanuts.All to play for imvho.
Thanks for that Kidlington
No royalties associated with CCS1477 ( as far as i am aware ) CellCentric have only 1 drug in their pipeline. Yes they have raised, but they aint going to buy PYC. That money raised is for the development of CCS1477 / Imobrodib. The only ones that would imho even think about buying is a larger pharma, that have oodles of projects going on.However they could still use PYC tech for a fraction of the cost of buying them out? So although its a nice idea of a buyout, its a non starter imho. Repeat biz is good, and will show other companies that savings can be made by using PYC. Prostate dosing tool is the potential company maker.
Have alot money to spend , I had a look at bicycle and they had about $250mln and a recent PYC client had raised $40mln and Cellcentric had $33mln
Maybe Baserite is correct ,why doesn't a client just buy Pyc as a whole company
Press ReleaseOctober 22, 2020
CellCentric raises $33m to broaden clinical trials of its first-in-class p300/CBP inhibitor, CCS1477
On the Cellcentric website there is a presentation of the data and it seems they are very excited ( see the final slide)
I don't know how to copy the slide sorry
https://www.cellcentric.com/publications/
https://www.cellcentric.com/publications/
This Is what was mentioned in 2020
The project will involve pharmacokinetic and pharmacodynamic modelling and build on the work completed over the course of 2019 in support of the clinical development of CellCentric’s lead asset CCS1477. This is a first in class small molecule inhibitor of p300/CBP, currently in Phase 1/2 trials for the treatment of late stage, drug-resistant prostate cancer as well as haematological malignancies.
A summary of some of the work that the Company has previously completed with CellCentric is available as a case study on the Physiomics website and can be accessed using the following hyperlink:
Good afternoon Kidlington
Do you think this might be the cause of the share price movement?
Maybe PYC will get royalties if this drug gets approved ?
https://twitter.com/CellCentric/status/1601908737668677632/photo/1
Nice to see them going from strength to strength. #PYC helped with CCS1477 / imobrodib.
Company is pleased to have bounced back to its highest ever level of total income for the year ended 30 June 2022 and sees opportunities for the current financial year in both its core consulting business and in personalised oncology. The global oncology pharmaceuticals market is anticipated to continue to grow strongly at around 11.6% per annum through 2027[1] with the biosimulation technology market (all therapy areas) predicted to grow even more strongly at 13% per annum through to 2030[2].
I still have a few which could pay for Xmas presents for kids with a jump to say 7p
I thought you were well out of this Utah
Last December
Let's see how quickly we can get there
Totally agree Laura. Lets stick to the facts. Physiomics is busy on a whole host of projects and news is due on the NHS trial shortly. Lets hope Monday continues to show a steady rise as it hits more investors radar. We know that shares are pretty scarce and the sp can move spectacularly both ways.
NHS Trust should complete recruitment by the end of September 2022 and data from the trial will be analysed over the course of the rest of this calendar year, with a particular focus on:
· Validating the ability of the tool to predict levels of neutropaenia
· Exploring the tool's ability to predict the effect of drugs commonly used to counteract the neutropaenia normally associated with chemotherapy (in this case the use of docetaxel in prostate cancer)
In parallel with the PARTNER study, the Company continues to be in dialogue with its US partner DoseMeRx (a subsidiary of TabulaRasa Healthcare Inc.) to identify commercially attractive applications of Physiomics technology that could potentially be marketing to US customers of the DoseMeRx platform.
I find it odd that people like Metcom whom I have never seen post on this board this year suddenly turn up and post negatives, the same happened on SCLP, LLOYD a others
I just don't understand the motivations of some people
Utar - stop being so pessimistic. The rise may also be next week!! If so - Woo Hah!
There is no Rns and there is nothing from Valrix either .
Someone is trying hard to pump so they can get out from shares .
Today, really nice to witness the buys come in. The buys were not extreme, but constant. I have no idea why is happened today?
No way is it a P/D as only few posts on twitter and not that many here imho.
I'd like to think its a "technical" bounce. However, as i have and others have stated before, December can be a news rich period. There has been good support for buys at the 2.25 area. If, as US says we drop on Monday with no RNS, well thats the market for you. Some traders will have bought in early doors, and will exit with their 10-20%. I do no believe that we wont see the recent lows of near 2p again, unless we get bad news.
Are we out the woods yet? No! Am i happier, only a smidge.
When JM said that he hoped to balance out the Merck contracts "throughout the year" instead of December, that appears to not have happened yet.
Roll on the Prostate decision tool.
I doubt its the VAL201 results that are the cause the rise today, from looking at the VAL RNS it seems as far away as ever imho.
The fall will next week.
Read the RNS - Jesus
In my view Val201 is just an added bonus
Of far.more importance is
hysiomics' strategy is to grow its consulting business (whether through fee for service or risk-sharing arrangements) while actively investigating other possible applications of our core modelling and simulation capabilities. Our main strategic aims are to:
· Form close partnerships with customers, attracting repeat business and growing alongside them (as evidenced by having now worked on multiple projects with Bicycle Therapeutics, Numab Therapeutics, Merck and others);
· Diversify the Company's customer base by working with a variety of commercial, and not-for-profit clients and grant funded projects (CRUK, Innovate UK, NIHR etc);
King ,
That is not true. How on Earth valrix can afford 6m to be paid Pyc? There isn’t 6m in the pot for sure,unless we get some money from 201 which isn’t going to happen any time soon .
Suzy can not rise 6m from share holders that’s is impossible.
Read the val board it’s been explained.Pump and dump with a Macao under 3mill with over £700,000 in cash and about break even.Whst you on about you clown?
PYC get £6 million from Val on them signing there deal.
PYC MC currently £3million ????????